Related references
Note: Only part of the references are listed.Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia
Ilona Baraniak et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Beyond binding: antibody effector functions in infectious diseases
Lenette L. Lu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
The pentameric complex drives immunologically covert cell-cell transmission of wild-type human cytomegalovirus
Isa Murrell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Anna Bootz et al.
PLOS PATHOGENS (2017)
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
David I. Bernstein et al.
VACCINE (2016)
Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus
Adam C. Finnefrock et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Immune correlates of vaccine protection against HIV-1 acquisition
Lawrence Corey et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The pathogenesis of human cytomegalovirus
Paul Griffiths et al.
JOURNAL OF PATHOLOGY (2015)
Identification of a Neutralizing Epitope within Antigenic Domain 5 of Glycoprotein B of Human Cytomegalovirus
Anna-Katharina Wiegers et al.
JOURNAL OF VIROLOGY (2015)
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies
Anna Kabanova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109
Ashley E. Fouts et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Structural Basis for the Recognition of Human Cytomegalovirus Glycoprotein B by a Neutralizing Human Antibody
Nadja Spindler et al.
PLOS PATHOGENS (2014)
Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: A different perspective of the host-pathogen interaction
Aura Muntasell et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies
Sinthujan Jegaskanda et al.
JOURNAL OF IMMUNOLOGY (2013)
Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus
Christian L. Jacob et al.
VIROLOGY (2013)
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
Peter D. Kwong et al.
NATURE REVIEWS IMMUNOLOGY (2013)
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells
Matthew B. Reeves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Human Cytomegalovirus Escapes a Naturally Occurring Neutralizing Antibody by Incorporating It into Assembling Virions
Kate Manley et al.
CELL HOST & MICROBE (2011)
Neutralizing Anti-gH Antibody of Varicella-Zoster Virus Modulates Distribution of gH and Induces Gene Regulation, Mimicking Latency
Kimiyasu Shiraki et al.
JOURNAL OF VIROLOGY (2011)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
Human cytomegalovirus immunity and immune evasion
Sarah E. Jackson et al.
VIRUS RESEARCH (2011)
B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies
Sonja Poetzsch et al.
PLOS PATHOGENS (2011)
Human Cytomegalovirus Glycoprotein B Is Required for Virus Entry and Cell-to-Cell Spread but Not for Virion Attachment, Assembly, or Egress
Marisa K. Isaacson et al.
JOURNAL OF VIROLOGY (2009)
Vaccine Prevention of Maternal Cytomegalovirus Infection
Robert F. Pass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers
David I. Bernstein et al.
VACCINE (2009)
Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences
Christophe Legendre et al.
CLINICAL INFECTIOUS DISEASES (2008)
Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection
Xiaohong Cui et al.
VACCINE (2008)
Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee
AM Arvin et al.
CLINICAL INFECTIOUS DISEASES (2004)
Share Paper
